DOWNSTREAM PROCESSING FEATURED ARTICLES
The Optima MAX-TL tabletop ultracentrifuge, from Beckman Coulter Life Sciences, delivers optimum functionality and efficiency within a compact and quiet package.
-
![morrisey_large]( "Tweaking Gene Expression To Repair Lungs")
Tweaking Gene Expression To Repair LungsLung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are on the rise, according to the American Lung Association and the National Institutes of Health.
-
![How Can You Mitigate The Risks Of Single-Use Bags?]( "How Can You Mitigate The Risks Of Single-Use Bags?")
How Can You Mitigate The Risks Of Single-Use Bags?The loss of product as a result of bag failure isn’t just an annoyance; it’s an expense, and a costly one at that. However, Chuck Hart, director of manufacturing at Prolong Pharmaceuticals, says with proper fitting and handling, these concerns can be mitigated.
-
Novasep Launches The Sius Single-Use TFF Skid, Completing The First 100 Per Cent Single-Use TFF Solution For Pre-Clinical To Clinical cGMP Biomanufacturing
Novasep, a leading supplier of purification solutions to the life sciences industries, recently announces the launch of its Sius single-use tangential flow filtration (TFF) skid.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Automated Bioluminescent ADCC Reporter Bioassay Using Bioengineered Jurkat Cells
Pharmaceutical companies are increasingly exploring new biologic and biosimilar products, and thus increasing monoclonal antibody (mAb) immunotherapeutic research. By Tracy Worzella, Promega Corporation and Brad Larson, Applications Department, BioTek Instruments, Inc.
-
![FiT_MaxiCaps-_20158]( "Accelerating Biopharmaceutical Development From DNA To Drug")
Accelerating Biopharmaceutical Development From DNA To DrugIn the last decade, single-use solutions for virtually every bioprocess unit have been developed, and considerable investments have been made by the industry into areas that underpin this technology.
-
Automation Of A Homogeneous Proximity Assay For Detection Of Residual Protein A In Biological Therapeutics
Protein A is used in affinity chromatography for therapeutic antibody purification and has been shown to leach from columns during purification of antibodies resulting in contamination. Residual Protein A in therapeutic drugs could elicit mitogenic or immunological reactions in patients.
-
![XDR-50MO]( "Microbial Fermentation In Single-Use Xcellerex™ XDR-50 MO Fermentor System")
Microbial Fermentation In Single-Use Xcellerex™ XDR-50 MO Fermentor SystemThis application note describes the performance of a single-use Xcellerex XDR-50 bioreactor system when used in cultivations of E. coli and of modified Pseudomonas fluorecsens (P. fluorescens) producing a monoclonal antibody (MAb). Both the achieved microbe densities and product yield were shown to be consistent with the performance of conventional stainless steel systems.
-
![DebottleneckingCartoon]( "Biomanufacturing Debottlenecking And Process Optimization")
Biomanufacturing Debottlenecking And Process OptimizationOptimizing biomanufacturing is particularly challenging because of variability and complexity associated with the sharing of finite and interdependent resources. By BIO-G
-
Removal Of Host Cell Proteins During Monoclonal Antibody Purification
Protein A chromatography is a widely used and highly successful method of purifying recombinant monoclonal antibodies. However, since Protein A has high affinity for antibodies, harsh conditions such as low pH are often required to elute monoclonal antibodies from Protein A affinity columns. By 3M Purification Inc
DOWNSTREAM PROCESSING PRODUCTS
ÄKTA™ chromatography systems can handle both simple and complex purification tasks and accelerate daily routines. All systems are controlled by UNICORN™ software, a common control platform and user interface for all scales of operation.
CHT is a leading purification medium of biomolecules in today’s demanding downstream process industry. Its mixed-mode support offers unique selectivities and often separates biomolecules that appear homogeneous with other chromatographic methods. The diverse binding capabilities of CHT for host cell proteins, leached protein A, antibody dimers and aggregates, nucleic acids, and viruses allow its use at any stage from initial capture to final polishing.
DOWNSTREAM PROCESSING MULTIMEDIA
Bioprocess With The Bozenhardts is back, with a fresh episode packed with advice from Herman and Erich on the selection of filling systems for biopharmas. Listen in as the Bozenhardts give us an update on the process, logistics, and administration trends that are informing filling system decisions today, and offer direction on making choices that will prepare you for the fast-advancing therapies of tomorrow.
Bio-Rad now offers two very high capacity ion exchangers: Nuvia S, which can be used for capture and/or intermediate polishing; and Nuvia Q, which can be used for intermediate and/or final polishing.